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Abstract
We report the clinical description and molecular dissection of a new fatal human inherited
disorder characterized by chronic auto-inflammation, invasive bacterial infections and muscular
amylopectinosis. Patients from two kindreds carried biallelic loss-of-expression and loss-of-
function mutations in HOIL1, a component the linear ubiquitination chain assembly complex
(LUBAC). These mutations resulted in impairment of LUBAC stability. NF-κB activation in
response to interleukin-1β (IL-1β) was compromised in the patients’ fibroblasts. By contrast, the
patients’ mononuclear leukocytes, particularly monocytes, were hyperresponsive to IL-1β. The
consequences of human HOIL-1 and LUBAC deficiencies for IL-1β responses thus differed
between cell types, consistent with the unique association of auto-inflammation and
immunodeficiency in these patients. These data suggest that LUBAC regulates NF-κB-dependent
IL-1β responses differently in different cell types.
Auto-inflammatory disorders are characterized by immune system hyperactivation in the
absence of autoantibodies, and self-reactive T cells 1. The genetic dissection of several auto-
inflammatory disorders has implicated two pro-inflammatory cytokines in these conditions:
interleukin (IL)-1β and tumor necrosis factor (TNF) 2,3. Autosomal dominant TNF receptor-
associated periodic fever (TRAPS) was the first genetic etiology of auto-inflammatory
disorders to be identified. It is caused by mutations in TNFRSF1A, resulting in the enhanced
activation of mitogen-activated protein kinases (MAPKs) and the secretion of pro-
inflammatory cytokines in response to lipopolysaccharide (LPS) 3. Inflammasomopathies
include autosomal dominant cryopyrin-associated periodic fever (CAPS, also known as
chronic infantile neurological cutaneous and articular syndrome (CINCA)/neonatal-onset
multisystem inflammatory disease (NOMID), Muckle Wells syndrome (MWS), familial
cold autoinflammatory syndrome (FCAS)), caused by mutation of NLRP3 (also known as
CIAS1), autosomal recessive familial Mediterranean fever (FMF), caused by mutation of
MEFV, autosomal recessive mevalonate kinase (MVK) deficiency, caused by mutation of
MVK, autosomal recessive deficiency of the IL-1 receptor antagonist (DIRA), caused by
mutation of IL1RN, and autosomal dominant pyogenic arthritis pyoderma gangrenosum and
acne (PAPA) syndrome, caused by mutation of CD2BP1. The clinical phenotypes of these
diseases result largely from enhanced IL-1β activity 2. All these auto-inflammatory
disorders are associated with recurrent episodes of fever, skin rash and aseptic organ
inflammation and may be complicated by metabolic abnormalities (e.g. 30% of TRAPS
patients develop amyloidosis) 1,3. Patients with these diseases are not generally prone to
unusual infectious diseases.
In sharp contrast, inborn errors decreasing TNF- and IL-1β-mediated immunity are
associated with severe infectious diseases in the context of impaired inflammation. Inborn
errors of NF-κB-mediated immunity are associated with impaired cellular responses to
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various stimuli, including TNF and IL-1β; these diseases include X-linked recessive and
autosomal dominant anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), due
to hypomorphic mutations of the NF-κB essential modulator (NEMO) gene and
hypermorphic mutations of the IKBA gene, respectively 4–7. Defects restricted to the Toll-
like receptor and IL-1R (TIRs) pathway, affecting the NF-κB, IRF3 and MAPK signaling
molecules, include autosomal recessive IRAK-4 and autosomal recessive MyD88
deficiencies 7–12. Patients with these two deficiencies are prone to the development of life-
threatening pyogenic bacterial diseases 10. The range of infections is much broader in
patients with NEMO and IκBα deficiencies 13. A characteristic of these four inborn errors
of immunity is that clinical and biological signs of inflammation are absent or delayed
during infectious episodes, although they may reach normal levels during prolonged
infection 13. For example, the induction of IL-6-dependent C-reactive protein (CRP) is
impaired in these patients 10,14. We report here the description and investigation of three
patients from two unrelated families displaying a paradoxical clinical phenotype combining
auto-inflammatory syndrome and pyogenic bacterial diseases 15. These patients also
developed muscular amylopectinosis, consisting of intracellular glycogen inclusions,
complicated by myopathy and cardiomyopathy, which have never previously been
associated with any inborn error of immunity. These patients carry loss-of-function
mutations in HOIL1 (RBCK1), a component of the linear ubiquitination chain assembly
complex (LUBAC). This E3 ligase complex, which adds head-to-tail linear polyubiquitin
chains to substrate proteins, has been implicated in NF-κB signaling 16,17.
Results
HOIL1 germline mutations in patients from two kindreds
The first kindred investigated (kindred A, French) was not consanguineous, but we
nonetheless hypothesized that the two sisters (P1 and P2) suffered from an autosomal
recessive disorder (Fig. 1a, case reports in supplementary note and Supplementary Fig. 1).
We set out to decipher the underlying genetic defect by two genome-wide (GW) approaches:
use of a GW human high-density SNP array (genome-wide investigations; GWI) to search
for large genetic lesions, including, copy number variations (CNV) in particular; and a
whole-exome sequencing (WES) approach to search for small genetic lesions, including
coding gene variations in particular 18–20. No homozygous candidate lesion was identified
by either approach, suggesting that the two patients might be compound heterozygous. We
therefore searched for heterozygous lesions in the same gene by GWI and WES. In both
patients, we found a single-copy loss of 31.799 kb on chromosome 20p.13, encompassing
the three last exons of TRIB3 and the first four exons of HOIL1 (also known as RBCK1)
(Fig. 1b). This deletion resulted from a genomic rearrangement due to non allelic
homologous recombination between intron 1 of TRIB3 and intron 4 of HOIL1 (named
TRIB3:g.-1272_HOIL1:g.9780del) (Supplementary Fig. 2a,b). The lesion was inherited
from the mother and was not transmitted to the healthy siblings. No other mutation in
TRIB3 was identified by WES or Sanger sequencing. By contrast, WES and Sanger
sequencing both showed that the two patients were heterozygous for the paternally derived
nonsense p.Q185X (c.553C>T) mutation in exon 5 of HOIL1 (Fig. 1c).
The second kindred investigated (kindred B, Italian) is consanguineous. The search for large
genetic lesions by GWI was not informative (Fig. 1a, case report in supplementary note). By
contrast, a homozygous deletion of CT at positions 121 and 122 (c.121_122delCT) in exon 2
of HOIL1 was identified in P3 by WES and confirmed by Sanger sequencing. This deletion
resulted in a frameshift (fs) and a premature stop codon (p.L41fsX7) (Fig. 1d). GW linkage
(GWL) and homozygosity mapping showed that the HOIL1 gene was located in a
chromosomal region linked to the disease (data not shown). Both parents and one healthy
sibling were heterozygous for the mutation. The three HOIL1 variants found in the two
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kindreds were not found in public databases (NCBI, UCSC, 1000 genomes) or in our own
GWI and WES databases of 124 and 621 individuals, respectively. They were also absent
from the 392 individuals of the CEPH-HGD panel tested, suggesting that they are not
irrelevant polymorphisms. HOIL1 encodes hemoxidized iron-regulatory protein 2 ubiquitin
ligase-1 (HOIL-1). HOIL-1 is one of the components of the linear ubiquitin chain assembly
complex (LUBAC), an E3 ligase complex that adds head-to-tail linear polyubiquitin chains
to substrate proteins 16,17. The large deletion in HOIL-1 in P1 and P2 was predicted, at the
very least, to result in the deletion of the ubiquitin-like (Ubl) domain (assuming that
translation is reinitiated; Fig. 1e). The small nucleotide deletion in the gene in P3 was
predicted to result in the deletion of all functional domains of HOIL-1. The nonsense
mutation in P1 and P2 was predicted to result in premature truncation within the novel zinc
finger (NZF) domain of HOIL-1. The Ubl domain is required for LUBAC formation and
linear ubiquitination 16. Collectively, these genetic data suggest that P1 and P2 from kindred
A are compound heterozygous, and P3 from kindred B is homozygous, for rare deleterious
alleles of HOIL1.
Impaired HOIL-1 expression in the patients’ cells
We assayed TRIB3 and HOIL1 mRNA by reverse transcription-quantitative PCR (RT-
qPCR) in SV40-transformed fibroblasts from patients and controls. The amounts of TRIB3
mRNA were normal in the patients’ cells (data not shown), whereas the amounts of HOIL1
mRNA were one third to a quarter those in the controls (Fig. 2a). Similarly, TRIB3 protein
was present in the patients’ cells (Fig. 2b), whereas HOIL-1 was undetectable by
immunoblotting with antibodies directed against the N-terminal (Fig. 2b) or C-terminal part
of the protein (data not shown). HOIL-1 was also not detectable in EBV-transformed B cell
lines (EBV-B cells) derived from P2 (data not shown). LUBAC is thought to consist of three
protein subunits: HOIL-1, SHANK-associated RH domain-interacting protein (SHARPIN,),
and HOIL-1 interaction protein (HOIP, also known as RNF31) 17,21–24. We thus assessed
the abundance of these three components of LUBAC in fibroblasts. In cells from the three
patients, SHARPIN protein levels were about 50 % lower than those in control cells (Fig.
2c) and HOIP was almost undetectable (Fig. 2c). It was therefore not possible to co-
immunoprecipitate SHARPIN with HOIP in cells from P1 (Fig. 2d). No lesion in HOIP or
SHARPIN was detected by GWI and WES in the three patients. We then used the patients’
fibroblasts (P1, P2) to investigate whether the expression of a wild-type (wt) HOIL1 allele
rescued LUBAC expression: HOIL-1 production was restored in the patients’ cells by stable
transfection with wt HOIL1 (Fig. 2e). This re-expression of HOIL-1 also restored expression
of the other two LUBAC components, HOIP and SHARPIN, to control levels (Fig. 2e).
These findings formally demonstrate that HOIL-1 is required for the overall stability of
LUBAC. Cells from the two compound heterozygous patients (P1 and P2) and from the
patient homozygous (P3) for HOIL1 mutations therefore displayed HOIL-1 deficiency,
resulting in a large decrease in the levels of the other two molecules normally present in
LUBAC.
Impaired NF-κB activation in the patients’ fibroblasts and B cells
It has been suggested that, at least on some cell types, LUBAC regulates activation of the
canonical NF-κB pathway, which plays a key role in inflammatory and immune responses.
We therefore assessed the functionality of the canonical NF-κB pathway in SV40-
transformed fibroblasts from the patients. The lack of HOIL-1 in the patients’ cells led to
lower levels of IKK kinase phosphorylation, slower IκBα degradation and a decrease in
NEMO ubiquitination in response to stimulation with either TNF or IL-1β (Fig. 3a,b). By
contrast, JNK phosphorylation in response to both stimuli was normal in the patients’
fibroblasts (Fig. 3a,b). The lower levels of NF-κB activation in the patients’ cells were
associated with lower NF-κB transcriptional activity, as assessed by NF-κB-reporter assays
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(Supplementary Fig. 3a). This impairment of the canonical NF-κB pathway led to weak
induction of the NF-κB target genes IL6 and A20, which are normally induced by TNF or
IL-1β (Supplementary Fig. 3b). Consistent with these RT-qPCR data, IL-6 production, as
assessed by ELISA, in response to TNF or IL-1β treatment was weak in cells from the
patients (Fig. 3c and Supplementary Fig. 4a,b), and the response to IL-1β was more severely
impaired than that to TNF. The induction of the NF-κB target gene products cIAPs (cellular
inhibitors of apoptosis) was weaker in cells from P2 than controls, and higher levels of
caspase-3 cleavage were observed in response to stimulation with TNF (Supplementary Fig.
4c). These observations indicated that HOIL1-deficient cells were more susceptible than
controls to TNF-induced apoptosis. The re-introduction of wt HOIL-1 into P1 fibroblasts
restored IKK kinase phosphorylation, IκBα degradation and IL-6 secretion in response to
both TNF and IL-1β (Fig. 3d-f). This confirmed that the HOIL1 mutant alleles in the
patients’ fibroblasts were responsible for the impairment of the NF-κB response to both
TNF and IL-1β. Analysis of IL-6 production by the patients’ fibroblasts following
stimulation with TLR2, TLR6 or TLR4 agonists indicated that these TLR pathways were
also partially affected (Supplementary Fig. 4d). IFN-β production following stimulation
with the TLR3 agonist poly(I:C) was abolished in fibroblasts from the patients, whereas
stimulation of the RNA helicase RIG-I with 7SK-AS or poly(I:C) plus Lipofectamine was
normal (Supplementary Fig. 4e). Likewise, stimulation with R-848 (a TLR7 and a TLR8
agonist) completely failed to induce TNF production by the patients’ EBV-B cells
(Supplementary Fig. 5a). Finally, IKK phosphorylation and IκBα degradation in response to
both IL-1β and CD40L were abolished in EBV-B cell lines from P2 (Supplementary Fig.
5b,c). Overall, NF-κB responses to all tested agonists of tumor necrosis factor receptor
(TNFR), IL-1R and TLR family members were impaired in fibroblasts and EBV-B cells
from patients with HOIL-1 deficiency.
Impaired NEMO recruitment to cytokine receptors
We investigated the molecular mechanisms underlying the defects in NF-κB activation in
HOIL-1-deficient fibroblasts. It has been suggested that LUBAC regulates NF-κB activation
by stabilizing the recruitment of the NEMO-IKK complex to the cytokine-activated
receptor 16,21,23,25–27. We therefore investigated the consequences of HOIL-1 deficiency for
NEMO recruitment to the TNF- and IL-1-R signaling complexes (RSCs). In control cells,
NEMO was rapidly and transiently recruited to the RSCs, and a clear enrichment in
ubiquitinated NEMO species was observed (Fig. 4a,b). However, in cells from the HOIL-1-
deficient patients, less NEMO was recruited to the TNF-RSC (particularly for the
ubiquitinated NEMO species) (Fig. 4a) and NEMO recruitment to the IL-1-RSC was almost
entirely abolished (Fig. 4b). SHARPIN recruitment to the RSCs was also reduced, especially
in response to IL-1β (data not shown). We then investigated the association between NEMO
and the polyubiquitinated adapter RIP1 in response to TNF and between NEMO and the
polyubiquitinated adapter IRAK-1 in response to IL-1β. Less NEMO was associated with
ubiquitinated forms of RIP1 in patient-derived than control fibroblasts, whereas the amount
of polyubiquitinated RIP1 present in the TNF-RSC was normal (Fig. 4c). Similarly, the
interaction between NEMO and ubiquitinated IRAK-1 in response to IL-1β was strongly
impaired in the patients’ cells, although the ubiquitination of IRAK-1 was unaffected (Fig.
4d). Thus, the absence of HOIL-1 affects the recruitment or stability of NEMO-IKK
complexes in response to both TNF and IL-1β, with the most severe defect being observed
for the IL-1-RSC.
Genome-wide impact of HOIL-1 deficiency in fibroblasts
These findings are generally consistent with the high incidence of opportunistic infections in
the HOIL1-deficient patients, which was similar to that of patients with impaired IL-1R-
and/or TNFR-dependent NF-κB immunity 5–7,13. However, unlike patients with these other
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immunodeficiencies, HOIL-1-deficient patients also presented with auto-inflammation and
amylopectinosis. We therefore investigated the effects of HOIL-1-deficiency on TNF and
IL-1β responses, by analyzing the GW transcriptional profiles (47,231 probes) of primary
fibroblasts from four healthy controls, three HOIL-1-deficient patients (P1, P2 and P3), one
MyD88-deficient patient and one NEMO-deficient fetus. In control fibroblasts, 544 and
2,208 transcripts were regulated by IL-1β after 2 hours and 6 hours of stimulation,
respectively, and 456 and 1,614 transcripts were regulated by TNF at the same time points
(Fig. 5). NEMO-deficient cells did not respond to either stimulus, whereas, as expected,
MyD88-deficient cells responded to TNF but not to IL-1β. By contrast, HOIL-1-deficient
cells were poorly responsive to IL-1β, as assessed after 2 h and 6 h; the response to TNF
was almost identical to that of control cells after 2 h, but was weaker than that of control
cells after 6 h. A more detailed analysis showed that control fibroblasts responded to IL-1β
and TNF by the rapid induction of inflammatory cytokines, chemokines and cell surface
receptors (e.g. the CCL5, CCL8, CXCL1, CXCL2, CXCL10, CXCR7, IL1β, and TNFAIP3
(also known as A20) genes). The upregulation of these transcripts after 6 h of IL-1β
stimulation was generally blunted in patients with HOIL-1 deficiency, although there were a
few notable exceptions (e.g. CCL2, CXCL1, IL8 and IL32). Thus, HOIL-1 deficiency in
human fibroblast cells results in the impaired expression of NF-κB-target genes in response
to IL-1β and, to a lesser extent, TNF. The GW transcriptome analysis data for fibroblasts
were therefore consistent with the in vitro investigations described above and, in particular,
with the receptor recruitment data (Fig. 4a,b): HOIL-1 deficiency and NEMO deficiency
shared many similarities, with only a few differences in terms of the fibroblast response to
IL-1β, whereas the responses to TNF were more discordant.
Genome-wide impact of HOIL-1 deficiency in leukocytes
We studied the basis of auto-inflammation in the patients further, by investigating their
leukocytes ex vivo. We first investigated the consequences of HOIL-1-deficiency, by
analyzing the GW transcriptional profiles of whole blood cells from P1 (without acute phase
and free of infection) in the absence of stimulation. We compared the transcriptional profile
of P1 with those of 41 healthy age-matched children and other patients with various
genetically determined auto-inflammatory disorders, including CAPS disorders (CINCA (2
patients) and Muckle-Wells syndrome (MWS, 5 patients)) and MVK deficiency (2 patients).
Blood cells from P1 had a unique gene expression profile (Fig. 6a and Supplementary Fig.
6a,b), with 2,900 transcripts up- or downregulated by a factor of at least two with respect to
healthy controls. Transcripts encoding HOIL-1, IFN-γ and several members of the TNF
family including CD30L (also known as TNFSF8) and APRIL (also known as TNFSF13)
were downregulated by a factor of at least two. Transcripts encoding the pro-inflammatory
cytokines IL-6, IL-6R and IL-6ST were upregulated in the patient’s blood ex vivo
(Supplementary Fig. 6b). Genes belonging to networks involved in cell death, the cell cycle
and cell signaling, the inflammatory response, immune cell trafficking and carbohydrate
metabolism were identified as being dysregulated in the patient. Using a pre-established
framework of transcriptionally coregulated transcripts, we demonstrated a distinct
upregulation of erythroid lineage- and ubiquitination-related transcripts that differentiated
the pattern of gene expression in the blood cells from this patient from those of patients with
NLRP3 and MVK mutations (Supplementary Fig. 6a). We also retrospectively studied the
concentrations of inflammatory markers and cytokines in plasma samples collected from P1
and P2 at various ages. Consistent with the clinical phenotype, background concentrations of
C-reactive protein (CRP) and IL-6 were high, increasing further during each inflammatory
episode (Fig. 6b). The concentrations of other pro-inflammatory cytokines, including IL-8,
TNF and IL-1β, and of some anti-inflammatory cytokines, notably the IL-1R antagonist,
were also high (Fig. 6b and data not shown). We then used ELISA to study the production of
cytokines by whole blood cells from P1 and P2 in response to stimulation (IL-1β, TLR
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agonists, two heat-killed pneumococcus strains and TNF). IL-1β and agonists of TLR1 and
TLR2 induced IL-6 production in both patients more strongly than in healthy controls,
whereas IL-10 production in response to treatment with TNF was abolished (Fig. 6c,d and
Supplementary Fig. 6c). Therefore, by contrast to the phenotype seen with fibroblasts,
leukocytes from these two HOIL-1-deficient patients appeared to be both constitutively
hyperinflammatory and hyperresponsive to IL-1β (but probably not TNF) ex vivo; this may
explain, in part, the patients’ auto-inflammatory syndrome in vivo.
Hyperactivation of HOIL-1-deficient mononuclear leukocytes
We further investigated the inflammatory phenotype observed in whole blood cells from
HOIL-1-deficient patients. We analyzed the GW transcriptional profiles of peripheral blood
mononuclear cells (PBMCs) from the three patients (P1, P2, P3), three healthy controls
(including two age-matched controls (C2 and C3)) and two MyD88-deficient patients
stimulated with TNF or IL-1β. The transcriptional profiles of PBMCs from HOIL-1-
deficient patients, healthy controls and MyD88-deficient patients were similar following
TNF stimulation (Fig. 7a-left panel). However, in response to IL-1β, HOIL1-deficient
PBMCs displayed an overinduction, with respect to healthy controls, of the transcription of
19 and 12 genes at 2 h and 6 h, respectively (Fig. 7a-right panel). As expected, leukocytes
from MyD88-deficient patients were unresponsive to IL-1β. The genes hyperinduced by
IL-1β in HOIL1-deficient cells included genes encoding pro-inflammatory cytokines: IL6,
MIP1A, MIP1B, IL8 and IL1B (Fig. 7b). We then investigated which PBMC subsets were
responsible for this hyperresponse to IL-1β in HOIL-1-deficient patients. PBMCs from P2,
seven healthy controls and one IRAK-4-deficient patient were stimulated with TNF, IL-1β,
LPS or PMA+ionomycin+CpG-B. The various PBMC subsets were identified according to
the cell surface expression of the following markers: CD3 (T cells), CD19 (B cells), CD56
(NK cells) and CD14 (monocytes). The production of IL-6, IL-8, MIP-1α, MIP-1β, IL-1β
and IFN-γ was assessed by intracellular staining and flow cytometry. In the CD3+, CD19+
and CD56+ cells from the controls, HOIL-1- and IRAK-4-deficient patients, no response to
TNF or IL-1β stimulation was observed (Supplementary Fig. 7a and data not shown). Upon
stimulation with PMA+ionomycin+CpG-B, CD3+ cells from P2 produced large amounts of
IL-8 (11% CD3+IL-8+ vs. 4% ± 3.8% in controls) whereas IFN-γ was produced in smaller
amounts (1% CD3+IFN-γ+ vs. 15%±7.3, Supplementary Fig. 7a). Monocytes from P2
produced four times more IL-6 than those from healthy controls upon IL-1β stimulation,
whereas IRAK-4-deficient monocytes were unresponsive (Fig. 7c, upper panels and
Supplementary Fig. 7b). Monocytes from P2 also produced large amounts of MIP-1α (Fig.
7c, middle panels), but the levels of IL-8, IL-1β and MIP-1β production were similar to
control values (Fig. 7c, lower panel and Supplementary Fig. 7a,b). Finally, healthy controls
and P2 monocytes responded similarly to LPS in terms of IL-6, IL-1β, and MIP-1α
production (Fig. 7c, upper panel and Supplementary Fig. 7a). In conclusion, the
hyperresponse of whole blood and PBMCs from HOIL-1-deficient patients to IL-1β appears
to be a consequence of the hyperresponsiveness of monocytes, probably accounting for the
clinical auto-inflammation in these patients.
Discussion
We have identified autosomal recessive HOIL-1 deficiency as the cause of a new clinical
entity combining invasive pyogenic bacterial infections, systemic auto-inflammation and
amylopectin-like deposits in muscle. HOIL-1, SHARPIN and HOIP are the three
components of LUBAC 17,22–24. SHARPIN and HOIP protein levels are low in the absence
of HOIL-1 and their restoration following HOIL-1 re-expression suggests that LUBAC is a
ternary complex. HOIP, the catalytic center of LUBAC 16,17, was almost undetectable in
fibroblasts and B cells from HOIL-1-deficient patients, suggesting that these patients are
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LUBAC-deficient. LUBAC is involved in the NF-κB pathway and conjugates linear
polyubiquitin chains onto specific Lys residues of NEMO 16. HOIL-1-deficient human
fibroblasts displayed impaired NF-κB activation, resulting in impaired NF-κB-driven gene
transcription and cytokine production in response to TNF and IL-1β, consistent with data in
mouse Hoil1 knockdown or knockout cells 16,27. However, TNF- and IL-1β-induced JNK
activity was normal in HOIL1-deficient human fibroblasts, whereas TNF-induced JNK
activity was enhanced in Hoil1−/− mouse embryonic fibroblasts (MEFs) 16,26. Overall, our
results demonstrate that human HOIL-1 and LUBAC are required for TNF- and IL-1β-
induced NF-κB responses, at least in fibroblasts.
LUBAC facilitates the recruitment of the NEMO-IKK complex to cytokine receptors, in at
least some cell types 27,29. We showed that the recruitment of human NEMO to TNF- and
IL-1-RSCs was compromised in HOIL-1-deficient fibroblasts. LUBAC-mediated linear
ubiquitination may facilitate the activation of IKK kinases; presumably, the attachment of
linear ubiquitin chains to NEMO 16 and, possibly, other components of the RSC 23 favors or
stabilizes the incorporation of NEMO into the RSCs. The recognition of these linear
ubiquitin chains by NEMO itself and, probably, by other components of the NF-κB cascade
may then lead to a local accumulation of IKK kinases, favoring their trans-phosphorylation
and activation. Alternatively, NEMO ubiquitination may induce a conformational change
required for activation of the associated kinases. However, the levels of NEMO
ubiquitination in response to TNF or IL-1β in the patients’ cells were only slightly lower
than those in control cells, whereas the amount of ubiquitinated NEMO recruited to the
TNFR or IL-1R correlated strongly with the signaling defect, as demonstrated by
transcriptome analysis. Our findings also suggest that human LUBAC is required for
optimal responses to other members of the TIR family, such as TLR3, and of the TNFR
family, such as CD40.
The susceptibility of these patients to invasive pyogenic bacterial disease is probably due to
impaired NF-κB-dependent responses to at least some key members of the TIR and TNFR
families in fibroblasts and, possibly, other cell types. Indeed, patients with inborn errors of
NF-κB-mediated or TIR-mediated immunity, carrying IκBα, NEMO, IRAK-4 or MyD88
mutations, are also prone to pyogenic bacterial infections 5,6,8,9,13. The infectious phenotype
of MyD88- and IRAK4-deficient patients is narrower than that of most patients with NEMO
or IκBα mutations 7,10,13. It may not be coincidental that IRAK-4-, MyD88- and HOIL-1-
deficient patients share a profound lack of response to TIRs and predisposition to pyogenic
bacterial diseases. One of the HOIL-1-deficient patients (P3) had a persistent
cytomegalovirus infection, but it is unclear whether this was a consequence of HOIL-1
deficiency. Unlike most IRAK-4- and MyD88-deficient patients, patients bearing mutations
in NEMO and HOIL1 are deficient in memory B cells and their antibody response to
pneumococcal glycans is impaired . Two patients died before hematopoietic stem cell
transplantation (HSCT) and the third died too soon after HSCT for any firm conclusions to
be drawn about a possible hematopoietic origin of the predisposition to infection, as in
patients with NEMO and IκBα deficiencies 13. Similarly, Hoil1−/− and Sharpin-deficient
(Sharpincpdm) mice are uninformative on this issue, as neither has been challenged with
pathogens 16,22–24,30.
Bacterial infections in patients with mutations in IκBα, NEMO, IRAK-4 or MyD88 are
associated with impaired inflammation 5–7,10,13,31, at odds with HOIL-1-deficient patients,
who even displayed inflammation in the absence of overt infection. The auto-inflammatory
phenotype of our patients is consistent with that of their mononuclear leukocytes, monocytes
in particular, which display constitutive over-transcription of numerous inflammatory genes
and are hyperresponsive to IL-1β1–3. The hematopoietic origin of the auto-inflammation in
HOIL-1-deficient patients is further supported by the fact that inflammation was controlled
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following HSCT in one HOIL-1-deficient patient. In the mouse, LUBAC seems to modulate
inflammatory responses by regulating NF-κB activation directly 16,17,21,23,25–27 and Hoil1-
deficient mice display no apparent excessive inflammation 24. However, Sharpincpdm
mice 22- 24,30,33 display severe eosinophilic inflammation and defective lymphoid
organogenesis 22–24,33–36. Consistent with this, the inflammatory disease in Sharpincpdm
mice is partially rescued by inactivation of the IL1RAP gene36, implicating IL-1β. The
inflammatory phenotype of HOIL-1-deficient patients therefore resembles that of
Sharpincpdm mice. Furthermore, inactivation of the TNF gene improves skin lesions in
Sharpincpdm mice 23 and anti-TNF antibody treatment in one HOIL-1-deficient patient
reduced the clinical inflammation. This improvement might have resulted from a decrease in
TNF-mediated IL-1β activity. Our study reveals that human HOIL-1 is anti-inflammatory:
patients lacking HOIL-1 display a strong auto-inflammatory phenotype.
Auto-inflammatory disorders may be complicated by metabolic disorders, with TRAPS
patients often developing amyloidosis, for example 1,3. The HOIL-1-deficient patients
displayed no amyloidosis, but had amylopectinosis, in the form of intracellular glycogen
inclusions in their muscles. Amylopectinosis has not been reported in Sharpincpdm and
Hoil1−/−mice 16,22–24,34. Several genetic etiologies of human amylopectinosis have been
reported 41–43. HOIL-1 deficiency is a novel cause of amylopectinosis involving unknown
mechanisms probably independent of IL-1, TNF and NF-κB, as amylopectinosis is not seen
in other disorders associated with enhanced or impaired NF-κB immunity 5–7,13. In
conclusion, the patients described here display a unique combination of clinical phenotypes,
highlighting the important and complex role of LUBAC in inflammation, immunity and
metabolism in humans. The paradoxical association of auto-inflammation and
immunodeficiency probably results from an imbalance between cellular responses, to NF-
κB-dependent pro-inflammatory stimuli at least, mediated by TIRs and TNFRs in particular.
The molecular basis of the immunodeficiency may be impaired responses to inflammatory
stimuli in fibroblasts, and possibly other non-hematopoietic cell types, whereas the auto-
inflammation may result from enhanced responses to IL-1β in leukocytes, including
monocytes in particular.
Methods
Sample collection
This study was conducted in accordance with the Helsinki Declaration, with informed
consent obtained from each patient or the patient’s family. The study was approved by the
local ethics committee of Necker-Enfants Malades Hospital, Paris, France, Spedali Civili
and Pediatric Clinic, University of Brescia, Brescia, Italy, and the Rockefeller University
Hospital, New York, USA.
Genetic analysis
Massively parallel sequencing—Genomic DNA extracted from the patient’s peripheral
blood cells was sheared with a Covaris S2 Ultrasonicator. An adapter-ligated library was
prepared with the Paired-End Sample Prep kit V1 (Illumina). Exome capture was performed
with the SureSelect Human All Exon kit (Agilent Technologies). Single-end sequencing was
performed on an Illumina Genome Analyzer IIx, generating 72-base reads.
Sequence alignment, variant calling and annotation—Sequences were aligned with
the human genome reference sequence (hg18 build), using BWA aligner 44. Downstream
processing was carried out with the Genome analysis toolkit (GATK) 45, SAMtools 46 and
Picard Tools (http://picard.sourceforge.net). Substitution and indel calls were identified with
a GATK UnifiedGenotyper and a GATK IndelGenotyperV2, respectively. All calls with a
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read coverage ≤2× and a Phred-scaled SNP quality of ≤20 were filtered out. All the variants
were annotated with the GATK Genomic Annotator.
Genome-wide human SNP array—Genomic DNA was isolated from the peripheral
blood of two patients, a healthy sister and parents, by the phenol/chloroform method. The
GeneChip Genome-Wide Human SNP Array 6.0 (Affymetrix) oligonucleotide-based array
was used. Data were analyzed with Affymetrix Genotyping Console 4.0 software and the
Affymetrix Genotyping Console Browser. The break points of the deletion on chromosome
20 were determined by PCR, with primers binding to intron 1 of TRIB3
(aattgactggaagatcctgacg) and intron 5 of HOIL1 (ggtacctccagcttccatctgg), flanking the
deleted regions. PCR products were sequenced on an ABI 3130× sequencer.
Cell lines, immortalization and complementation
Control and patient-derived fibroblasts were immortalized by transfection with a plasmid
expressing SV40 large-T antigen. Transformed cell lines were grown in DMEM (Gibco)
supplemented with 10% fetal calf serum (Gibco). The NEMO−/− fibroblasts were kindly
provided by Asma Smahi 47. HOIL1 mRNA was reverse-transcribed, amplified and inserted
into the retroviral vector pMSCV (Clontech). Infectious viral particles were produced by
cotransfecting GP2-293 packaging cells with pVSV-G and pMSCV-HOIL-1 or an empty
vector (Clontech). Viral particles were collected 48–72 hours after transfection and used to
infect SV40-transformed fibroblasts. Infected cells were selected with 0.4 μg/ml puromycin
(Invitrogen).
Antibodies and reagents
The antibodies used for detection on immunoblots were anti-HOIL-1 N-ter (provided by
Henning Walczak) 27, anti-HOIL-1 C-ter (provided by Kazuhiro Iwai) 21, anti-TRIB3
(2488-1, Epitomics), anti-HOIP (PAB6229, Abnova), anti-NEMO (sc-8330, Santa Cruz and
#611306, BD), anti-SHARPIN (14626-1-AP, ProteinTech), anti-IκBα (#610690, BD), anti-
phospho-IKKα-β (ser176/180) (16A6, Cell Signaling), anti-IKKβ (AM8109a, Abgent),
anti-phospho-JNK (G-7, Santa Cruz), anti-JNK (sc-571, Santa Cruz), anti-IRAK1 (sc-7883
and sc-5288, Santa Cruz), anti-RIP1 (#610458, BD), anti-IL-1R1 (04-465, Millipore), anti-
TNF-R1 (H-5, Santa Cruz), anti-cIAP (MAB3400, R&D Systems), anti-cleaved caspase-3
(Asp175) (9661, Cell Signaling), anti-β-tubulin (T4026, Sigma-Aldrich) and anti-GAPDH
(sc-81545, Santa Cruz) antibodies. Species-specific secondary antibodies coupled to
horseradish peroxidase were obtained from Vector Laboratories or Amersham-Pharmacia.
Cell lysis, immunoprecipitation and immunoblotting
Cells were lysed in a buffer containing 30 mM Tris-HCl pH 7.5, 120 mM NaCl, 2 mM KCl,
1% Triton X-100 and 2 mM EDTA supplemented with protease and phosphatase inhibitors
(Complete and PhoStop, Roche). For immunoprecipitations, antibodies (5 μg) were added to
1 mg of total protein extract and incubated overnight at 4°C. Protein-A or protein G agarose
beads (Sigma-Aldrich) were added to the samples, which were then incubated for 1 hour at
4°C. For experiments involving Flag-TNF and Flag-IL1-β treatments, cleared supernatants
were incubated with anti-Flag M2 affinity gel (Sigma-Aldrich) for 2 hours at 4°C. For
experiments involving biotinylated TNF treatments, cleared supernatants were incubated
with streptavidin-agarose (Sigma-Aldrich) for 2 hours at 4°C. In all cases, beads were
washed three times with lysis buffer and resuspended in Laemmli buffer. Proteins were
separated by SDS–PAGE and transferred to PVDF membranes. Immunoreactive proteins
were visualized by chemiluminescence. The relative amounts of HOIP and SHARPIN were
determined with Quantity One software (Bio-Rad). For NF-κB-dependent reporter assays,
SV40-transformed fibroblasts were transiently transfected with the NF-kB-dependent firefly
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luciferase plasmid pGL4.32 (Promega) and the Renilla luciferase plasmid as an internal
control, in the presence of Lipofectamine™ LTX reagent (Invitrogen). After 24 hours, cells
were stimulated with TNF or IL-1β for four hours and luciferase activities were assessed
with the dual luciferase assay kit (Promega).
Gene expression and microarray analysis
RNA was extracted from SV40-transformed fibroblasts with Trizol (Invitrogen) and reverse-
transcribed (2 μg) with the SuperScript III first-strand synthesis kit (Invitrogen). HOIL1,
TRIB3, A20 and IL6 mRNAs were quantified by RT-qPCR in a TaqMan Gene Expression
Assay, with normalization against GUS probes.
Data acquisition—Whole blood cells from patients and healthy donors were collected and
total RNA was extracted using the MagMAX-96 Blood RNA Isolation Kit (Applied
Biosystems). Primary fibroblasts and PBMCs from patients and healthy donors were
stimulated with IL-1β or TNF for 2 or 6 hours. Total RNA was isolated from fibroblasts and
PBMCs with the RNeasy Mini Kit (Qiagen). RNA integrity was assessed on an Agilent
2100 Bioanalyzer. Biotinylated cDNA targets were prepared with the Illumina TotalPrep
RNA Amplification Kit (Ambion) and hybridized to Illumina human HT-12 Expression
Microarray Chips.
Data preprocessing—For the analysis, the background was subtracted and the raw signal
values were extracted with Beadstudio v2 software (Illumina) and scaled by quantile
normalization. The minimum intensity was set to 10, and all the intensity values were log2-
transformed. Only the probes called as present in at least one sample (p<0.01) were retained
for downstream analysis (n=26,607).
Data analysis—Raw data were first subjected to background subtraction and scaled to the
average with Genome studio software (Illumina). They were then analyzed with Genespring
software (Agilent). The minimum intensity was set to 10, and the intensity values were log2-
transformed. For the analysis of ex-vivo whole blood samples, all samples were normalized
with respect to the median intensity for control samples. After filtering out non-expressing
probes, at least a two-fold difference in expression between patient 1 and 41 healthy controls
was observed for 2,900 transcripts. A pre-established set of transcriptional modules was
used as a framework for microarray data analysis. The approach used to construct this
framework has been described elsewhere 48. Genes with coordinated expression within or
across nine human disease datasets were selected in multiple rounds of clique and paraclique
clustering, to form a transcriptional module framework. The percentage of transcripts
significantly up- or downregulated with respect to healthy controls (p<0.05, assuming equal
variance) in each module was visualized on module maps. For the analysis of primary
fibroblasts, transcripts without detectable expression changes (difference in normalized
expression of less than 2-fold in either direction, in all samples) or absent from the dataset
(as defined by an Illumina detection p-value greater than 0.01 in all samples) were filtered
out, leaving 13,693 transcripts for downstream analysis. Stimulated samples from each
donor were normalized with respect to their non stimulated reference sample. We identified
the genes differentially regulated upon IL-1β or TNF stimulation in healthy donors on the
basis of transcripts displaying a change in signal intensity of at least two-fold (up- or
downregulation) with respect to the non stimulated control. We then investigated the
expression of these genes in samples from the patients.
Cell stimulation, ELISA and FACS analysis
Cells were stimulated with the following cytokines and agonists: TNF, biotinylated-TNF
and IL-1β (R&D Systems), Flag-TNF and Flag-IL1β (Alexis Biochemicals), Mega-CD40L
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(Enzo), LPS (Sigma-Aldrich), phorbol-12-myristate-acetate (Sigma-Aldrich), ionomycin
(Sigma-Aldrich) and CpG-B (Invivogen). For cytokine production by whole blood cells,
blood was first mixed with an equal volume of RPMI, left untreated for 48 hours and then
treated with cytokines or agonists for the indicated time. IL-6 and IL-10 secretion levels
were determined with ELISA kits (M9316 and M1910, Sanquin).
Frozen PBMCs were washed twice with FCS-containing medium and used to seed 48-well
plates (106 cells/well). They were cultured for 4–6 hours and then stimulated with TNF (20
ng/ml), IL-1β (10 ng/ml), LPS (10 ng/ml) or PMA+ionomycin+CpGB (10−9 M/10−7 M/100
μg/ml). Concomitantly to stimulation, protein transport was blocked with GolgiStop and
GolgiPLug (BD). Cells were stained with anti-CD3 (BD, #560366), anti-CD19 (BD,
#340951), anti-CD14 (BD, #557742), anti-CD56 (Biolegends, #318331) antibodies for
cellular phenotyping and with Aqua Live/Dead (Invitrogen) to exclude dead cells. After
fixation and permeabilization (BD, #554722), the cells were stained with antibodies against
IL6 (BD, #561441), MIP-1α (BD, #554730), MIP-1β (BD, #560565), IL-1β (BD, #340515),
IL-8 (BD, #511410) and IFN-γ (BD, #559326). Stained PBMCs were captured by flow
cytometry with a BD LSRII flow cytometer and FACS Diva software. The data were
analyzed with FlowJo (© Tree Star).
Histology and immunohistochemistry
Samples from the gut, heart and skeletal muscles of patients and healthy controls were
studied. All cases were reviewed by two expert pathologists to confirm diagnosis. Formalin-
fixed paraffin-embedded tissue blocks were cut into 4-μm sections that were stained with
hematein-eosin (HE) and periodic acid-Schiff (PAS) reagent before and after diastase
digestion. Images were acquired with a Leica DM LB2 microscope at a magnification of
×400 and a Leica DFC 280 camera. Slides were digitized with a Hamamatsu Nanozoomer.
Statistics
GraphPad Prism software was used to conduct unpaired, two-tailed Student’s t tests for
sample analysis or one-way ANOVA followed by Tukey’s multiple comparison test. Values
of p < 0.05 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Two kindreds with autosomal recessive HOIL1 deficiency
a) Pedigree of kindred A, showing the segregation of the 31.799 kb deletion of chromosome
20 (del: TRIB3:g.-1272_HOIL1:g.9780del) encompassing TRIB3 and HOIL1, and the
nonsense c.553 C>T, p.Q185X mutant allele in HOIL1. Pedigree of kindred B, showing the
segregation of the HOIL1 deletion c.121_122delCT, p.L41fsX7. The arrow indicates the
index case. b) Schematic representation of the deletion encompassing the two genes, with
the loss of one copy of the allele from individuals A.I.2, P1 and P2. In the lower panel, a
PCR-based approach involving amplification of a 1.235 kb fragment with genomic TRIB3
and HOIL1 primers reveals the deletion. c–d) HOIL1 DNA sequence electropherograms, for
a control and the patients c) from kindred A, for the region corresponding to the nonsense
mutation and d) from kindred B, for the region corresponding to the deletion. e) Schematic
diagram of the HOIL-1 protein. Ubiquitin-like (Ubl), novel zinc-finger (NZF), ring (RING)
and in-between RING (IBR) domains are shaded in gray. Arrows indicate the nonsense and
deletion mutations and the double arrow indicates the deletion of the first four exons in
HOIL1. Exon boundaries are indicated by vertical dashed bars and amino-acid positions are
numbered.
Boisson et al. Page 15
Nat Immunol. Author manuscript; available in PMC 2013 June 01.
$watermark-text
$watermark-text
$watermark-text
Figure 2. HOIL-1 complete deficiency
a) Relative expression of HOIL1 in SV40-immortalized fibroblasts from controls (C1 and
C2) and patients (P1, P2 and P3). b) HOIL-1 and TRIB3 immunoblots of total cell extracts
from SV40-immortalized fibroblasts derived from controls and patients. c) Low levels of
HOIP and SHARPIN in the absence of HOIL-1 in SV40-immortalized fibroblasts. d) No
HOIP-SHARPIN co-immunoprecipitates can be detected in HOIL-1-deficient fibroblasts.
Immunoprecipitation experiments were performed with either control mouse IgGs (isotype)
or mouse antibodies against the N-terminus or C-terminus of HOIP in control or P1 patient-
derived fibroblasts. HOIP and co-immunoprecipitated SHARPIN were detected by
immunoblotting. e) Re-expression of HOIL-1 in fibroblasts from patients restores HOIP and
SHARPIN protein levels. A retrovirus-based strategy was used for stable re-expression of
the wt HOIL1 allele in fibroblasts from P1 and P2. Fibroblasts infected with empty viruses
were used as controls. Data are representative of three experiments (a), four experiments (b),
three experiments (c), three experiments (d) or four experiments (e).
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Figure 3. HOIL-1 is required for full TNF-α and IL-1β-induced activation of NF-κB in HOIL-1-
deficient fibroblasts
a) Impaired NF-κB activation in response to TNF. Time-course of TNF-stimulated SV40-
immortalized fibroblasts, showing impaired IKK kinase phosphorylation, lower levels of
NEMO ubiquitination (indicated by an asterisk) and slower IκBα degradation in patients
than in controls. JNK phosphorylation in response to TNF is identical in control and patient
cells. b) Impaired NF-κB activation in response to IL-1β. Time-course of IL-1β-stimulated
SV40-immortalized fibroblasts showing impaired IKK kinase phosphorylation (upper
panel), lower levels of NEMO ubiquitination (indicated by an asterisk) and slower IκBα
degradation in patients than in the controls. JNK phosphorylation in response to IL-1β is
identical in control and patient cells. c) Low levels of IL-6 production in response to TNF
and IL-1β in SV40-immortalized fibroblasts from HOIL-1-deficient patients (P1, P2, P3).
All numerical data are means ± SEM. * p<0.05, ** p<0.01, *** p<0.001, ns, not significant.
d–e) Re-expression of HOIL-1 restores the TNF- and IL-1β-induced activation of NF-κB.
The kinetics of TNF and IL-1β stimulation in the indicated cell lines was followed by
determining the levels of phospho-IKKs, IκB α and NEMO by immunoblotting. GAPDH
was used as a control. f) HOIL-1 complementation restores TNF-and IL-1β-induced IL-6
production in fibroblasts from P1 and P2. IL-6 levels in the supernatants of mock-, TNF-
and IL-1β-treated cell lines were assayed by ELISA. All numerical data are means ± SEM.
(** p<0.01). Data are representative of three experiments (a,b), three experiments (c), two
experiments (d,e) or three experiments (f).
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Figure 4. Impaired recruitment of NEMO to cytokine receptors in the patients’ fibroblasts
a) HOIL-1 deficiency impairs the recruitment of NEMO to the TNF-RSC. Flag-tagged TNF
was used to activate and isolate the TNF-RSC. Cells were lysed, TNF-RSC was purified on
Flag-affinity resin and complex-associated NEMO was analyzed by immunoblotting. b)
HOIL-1 deficiency abolishes NEMO recruitment to the IL-1-RSC. The same strategy as in
a) was used, except that Flag-tagged IL-1β was used to stimulate the cells and to isolate the
IL-1-RSC. The abundance of TNFR (a) and IL-1R (b), assessed by immunoblotting, was
similar in control and patient-derived fibroblasts. c) HOIL-1 deficiency impairs the
interaction between NEMO and polyubiquitinated RIP1 in response to TNF. NEMO
(NEMO-IP) was immunoprecipitated from lysates of control and patient fibroblasts treated
with biotinylated TNF and analyzed by immunoblotting for NEMO, RIP1, and IKKβ. The
total amount of the ubiquitinated forms of RIP1 associated with the TNF-RSC was evaluated
by streptavidin pulldown followed by immunoblotting for RIP1. d) HOIL-1 deficiency
impairs the interaction between NEMO and polyubiquitinated IRAK-1 in response to IL-1β.
NEMO and IRAK-1 were immunoprecipitated from lysates of IL-1β-treated fibroblasts and
subjected to western blotting for NEMO or IRAK-1 as indicated. These data are
representative of three experiments.
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Figure 5. Transcriptome analysis of TNF or IL-1β stimulation of primary fibroblasts
Primary fibroblasts from four healthy donors, P1, P2, P3, MyD88- and NEMO-deficient
cells were stimulated with TNF or IL-1β for 2 and 6 hours. Stimulated samples were
normalized with respect to the corresponding non stimulated reference sample. The heat
maps represent hierarchically clustered transcripts displaying up- or downregulation by a
factor of at least two in stimulated healthy control samples (averaged).
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Figure 6. Whole blood analysis reveals a new hyperinflammatory disorder in HOIL-1-deficient
patients
a) Transcriptional profiles of whole blood from patients with hyperinflammatory conditions
(CINCA, MWS, MVK) and HOIL-1-deficient patients. Comparison of the transcriptional
profile of P1 with those of 41 healthy age-matched children (not shown) and other patients
with CAPS (2 CINCA, 5 MWS and 2 MVK patients). P1 presented a distinct pattern of gene
expression in the blood, with 2,900 transcripts up- or downregulated by a factor of more
than two with respect to healthy controls. Red, blue and yellow indicate a relative increase,
decrease and no change in expression levels respectively. Samples are ordered by donor:
HOIL-1-deficient patient (P1, lane 1), CINCA patients (lanes 2–3), MWS patients (lanes 4–
8) and MVK-deficient patients (lanes 9–10). b) Quantification of various cytokines in
plasma samples. The amounts of IL-1RA (an IL-1 antagonist), TNF, IL-6 and CRP were
determined in plasma samples from healthy donors, P1 and P2 taken at various ages.
Individuals with CRP concentrations above 3 mg/ml were considered to have an
inflammatory condition. c) IL-6 secretion by whole-blood cells from 30 healthy donors and
HOIL-1-deficient patients (P1, P2), treated with IL-1β for 48 hours. All numerical data are
means ± SEM, *** p<0.001 d) IL-10 secretion by whole-blood cells from healthy donors
and HOIL-1-deficient patients (P1, P2) and the heterozygous parents (I.1, I.2), activated by
incubation with TNF or PMA+ionomycin for 48 hours. nd: not detectable
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Figure 7. HOIL-1-deficient monocytes display hyperproduction of IL-6 upon IL-1β stimulation
a) Transcriptional profile of leukocytes from P1, P2 and P3 after 2 and 6 hours of
stimulation by TNF or IL-1β. The median gene expression in HOIL-1- or MyD88-deficient
patients (y-axis) was plotted against the median gene expression sorted by ascending order
of fold induction in the healthy controls (two of whom were age-matched). Each dot
corresponds to one probe. b) Levels of IL6, IL8, MIP1A, MIP1B and IL1B mRNA in 3
healthy controls, 3 HOIL-1- (P1, P2 and P3) and 2 MyD88-deficient patients, extracted from
the microarray data. Each dot corresponds to one probe in one individual. The number of
probes per gene is 1 for IL6 and IL1B, 2 for MIP1B and IL8 and 4 for MIP1A. The non
parametric Mann-Whitney test was used for statistical analysis (* p<0.1, ** p<0.05, ***
p<0.005). c) Cytokine production in CD14+ cell subsets determined by intracellular staining
of stimulated PBMCs. PBMCs from P2, 7 healthy controls and 1 IRAK-4-deficient patient
were stimulated with TNF, IL-1β or LPS. The secretory pathways were concomitantly
blocked with monensin and brefeldin A. Twelve hours after stimulation, the cells were
immunolabeled with antibodies against CD14 and then permeabilized to assess the
production of IL-6, MIP-1α and IL-8. Cells were analyzed by flow cytometry. (n=1).
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